Summary Survival analysis has found widespread applications in medicine in the last 10-15 years. However, there has been no published review of the use and presentation of survival analyses. We have carried out a systematic review of the research papers published between October and December 1991 in five clinical oncology journals. A total of 132 papers were reviewed. We looked at several aspects of study design, data handling, analysis and presentation of the results. We found that almost half of the papers did not give any summary of length of follow-up; that in 62% of papers at least one end point was not clearly defined; and that both logrank and multivariate analyses were frequently reported at most only as P-values [63/84 (75%) Survival analysis has found widespread applications in medicine in the last 10-15 years (Andersen, 1991), particularly in clinical oncology, and its correct application and presentation is critically relevant for much of the cancer literature. Although the use of statistical methods in medicine has been subjected to much scrutiny (see Altman, 1982 Altman, , 1991 , we believe that there has not been any published review of the use of survival analysis methods in medical journals. Hence, we have carried out a systematic review of the appropriateness of the application and presentation of survival analyses in clinical oncology journals. We have focused on the size of the studies being published, the adequacy of the description of the data analysed (with particular interest given to the length and quality of follow-up and the clarity of the end points of interest) and the choice and quality of univariate, multivariate and graphical analyses. In the light of disappointing findings, we discuss existing guidelines and present some new guidelines aimed in particular at presentation.
Survival analysis has found widespread applications in medicine in the last 10-15 years (Andersen, 1991) , particularly in clinical oncology, and its correct application and presentation is critically relevant for much of the cancer literature. Although the use of statistical methods in medicine has been subjected to much scrutiny (see Altman, 1982 Altman, , 1991 , we believe that there has not been any published review of the use of survival analysis methods in medical journals. Hence, we have carried out a systematic review of the appropriateness of the application and presentation of survival analyses in clinical oncology journals. We have focused on the size of the studies being published, the adequacy of the description of the data analysed (with particular interest given to the length and quality of follow-up and the clarity of the end points of interest) and the choice and quality of univariate, multivariate and graphical analyses. In the light of disappointing findings, we discuss existing guidelines and present some new guidelines aimed in particular at presentation.
Methods
We examined all papers published in British Journal of Cancer, European Journal of Cancer, Journal of Clinical Oncology and American Journal of Clinical Oncology between October and December 1991 which included analyses of survival data. There were 132 papers which reported at least one of the following: Kaplan-Meier or actuarial survival curves; logrank or related tests; parametric or semiparametric survival analyses. Those papers with survival data which did not present any of these analyses, and thus were not included, were largely phase I or II clinical trials.
The 132 papers were reviewed using a standard form that had been tested in a small pilot study of 20 papers which were read by all four authors. When the form was finalised each paper was read by two of the authors according to a balanced randomisation scheme. Disagreements between reviewers were resolved in paired discussions and by discussion between all four reviewers on the rare occasions when it was necessary.
The assessment form included separate sections relating to distinct aspects of each paper. It also included the time taken by each author to extract the information from the paper onto the form as an indication of the clarity of each paper. The form is available from the authors upon request; the contents of the form are summarised below.
Sample size
The importance that can be attached to the results from a survival analysis depends on the selection and number of subjects included. Hence, for each paper we recorded the number of subjects studied and the maximum and minimum number of subjects analysed by survival methods. The number of events (e.g. deaths), which determines the statistical power of a survival study, was also recorded.
Follow-up
The interpretation of the results of a survival analysis depends in great measure upon the time frame in which the study was carried out and the completeness of follow-up of the subjects being investigated. Three critical dates define the start and end of patient accrual and the cut-off date for the analysis (Shuster, 1991) . We checked whether these dates were reported and also whether a summary of the length of follow-up (such as a median) was given. We also noted whether the authors mentioned if any subjects were lost to follow-up and, if so, whether there was a statement on how these were treated in the analysis. In order to evaluate the quality of the reviewed papers, we therefore recorded the number of end points studied in each paper, whether their time origin was stated, whether censoring events were clearly reported and when relapse-free survival analyses were carried out whether it was clear which patients were included.
Explanatory variables
When the effects of prognostic factors are examined using survival analysis the results may be affected by the number of variables examined, their coding and the presence of missing values. We therefore recorded the total number of variables examined in univariate analyses and the maximum number of variables examined in multivariate analyses, whether continuous variables were recoded, and how they were categorised. We also noted if missing values were reported and discussed.
For many survival analyses it is important that the variables are measured at or before the time origin, otherwise their observation depends on what happens to the patient between the time origin and the measurement of the variable. An example is response to treatment when the time origin is diagnosis. Comparisons of the survival probabilities of responders and non-responders, where survival is measured from diagnosis, are still seen in the literature despite many published warnings against them (Anderson et al., 1985; Simon and Wittes, 1985) . We recorded whether such incorrect analyses were reported.
Continuous explanatory variables need to be categorised to produce survival plots and perform some types of analyses. We recorded whether variables were reduced to two or more categories and whether the choice of cut-off points was explained. We recorded whether cut-off points were derived from the data by minimising the associated P-value. This so-called 'optimal' cut-off point approach is seriously flawed, leading to overestimates of prognostic importance and Pvalues that are far too small .
Graphical presentation
An accurate description of a data set in terms of survival is provided by Kaplan-Meier or life table estimates, which are usually presented in the form of a graph. We recorded the type of survival curve and number of survival plots presented. We also considered the quality of graphs; how points in the graph were joined (steps are appropriate); whether there were any marks indicating censoring times and if so whether they were identified; whether the number of subjects at risk or confidence intervals were given at any time; and whether the numerical axes were reasonable. When survival curves were presented for more than one group of patients, we We noted whether the authors discussed the model-building strategy (e.g. using stepwise analysis), the model assumptions and the goodness of fit of the final model. We also recorded the type of information presented to summarise the results, including estimated regression coefficients, hazard ratios, Pvalues and the computation of prognostic indices.
Subset analyses
We defined a subset analysis as one which did not use the full number of subjects who could be used. We were interested in whether any subset analyses were performed and, if so, whether they were the main purpose of the paper. We examined in particular how the analyses of complementary subsets (e.g. patients with different stages of the disease) were performed. The reporting of separate analyses on each subset may lead to erroneous conclusions; tests for interaction are more appropriate (Simon, 1982; Simon and Altman, 1994) . However, tests for interaction not recommended in small samples owing to low power.
Abstracts
The abstract has many functions, the most important for this study being the correct summary of results and conclusions. We recorded whether a summary of follow-up was men-tioned and whether and how univariate and multivariate analyses were reported. None of the journals in the study used structured abstracts (Haynes et al., 1990) at the time of the review.
Miscellanea
The majority of survival analyses are performed with the help of computer programs. We noted if any information was given in the papers about the commercial software used to analyse the data.
As an overall appraisal of each paper we made subjective assessments of the quality (recorded as adequate or not) of the analyses, the description of the statistical methods and the style of the graphical presentation. Since these assessments were subjective, 'not adequate' was noted if either reviewer recorded this option.
Further, to evaluate whether known statistical involvement improved the quality of a paper, we noted if any author was a member of a department of statistics or epidemiology.
Finally, we recorded any peculiarities which we noticed in the papers and which were not covered by questions in the form. They are reported in the relevant sections.
Results
The 132 papers in the study included 11 from the British Journal of Cancer, 52 from Cancer, 20 from the European Journal of Cancer, 32 from the Journal of Clinical Oncology and 17 from the American Journal of Clinical Oncology. They represent, respectively, 11%, 27%, 20%, 60%, 59% of all papers published in the journal between October and December 1991. Papers from all journals were considered together; it was not our intention to compare journals.
Most of the papers described clinical trials (51%) or retrospective observational studies (45%). Of the former, only 18 papers were about controlled clinical trials, and of the latter only eight were treatment related. The remaining six papers included a case-control study, the data from a prospective screening study, three papers each describing analysis on selections of patients from several randomised clinical trials and one paper which gave no information on sample recruitment.
Reading the papers and completion of the form took a median of 30 min per reader (range 12-80 min).
Sample size
The number of subjects in each analysis was not always clear. A total of 123 papers out of 132 stated the number of patients included in the study and the numbers examined in survival analyses. In 21 out of 123 (17%) papers some study patients were excluded from all survival analyses. Seventeen included in their survival analyses a maximum of fewer than 30 patients and three papers a maximum of fewer than 15.
Many studies (78/126 with clear information, 62%) included one or more additional survival analyses on a selection of the subjects already analysed. Most of these papers (47/78) included subsidiary analyses of less than half of the patients included in the main survival analysis. Moreover, about a third of these papers (29/78) included analyses of fewer than 30 subjects, and six fewer than 15 subjects.
Fewer than half (45%) of the papers gave the number of events for each end point, with only two-thirds giving the number of events for at least one of the end points analysed within the paper.
Follow-up Fewer than a quarter of papers reported all three dates of start and end of accrual and cut-off point for the analysis ( Table I ). The majority of the papers gave only the accrual period, and nearly half of these (37/77) did not include any summary of follow-up time. Several of the papers which did not report any dates also did not summarise follow-up (9/16; see first row in Table I ).
Almost half of the papers did not give any summary of follow-up. In at least two cases the event of interest had been recorded for all patients by the time of the analysis, making a summary of follow-up unnecessary. For those which did give a summary, the median follow-up time was the most frequent value presented, although the method used to compute it was rarely specified (16/52, 31%). The other summaries reported in these papers were the mean follow-up time, which is inappropriate in most cases because of the likely skewness of the observed survival times, and the range of follow-up times (or only the minimum), which only reports the most extreme cases and therefore is not very informative.
Losses to follow-up were mentioned in 34 papers, of which 12 declared no losses and the remaining 22 reported that losses had occurred. However, 12 out of these 22 did not state how losses were treated in the analyses.
Endpoints
The identification of end points was one of the hardest aspects of the assessment of papers. In many papers one or more end points was not clearly defined. Many papers referred to 'overall survival'. We took this to imply that the end point was death from any cause, but it would be unsafe to assume that such usage was the rule, as in at least one paper the term overall survival related to cancer deaths only.
With the exception of one paper, between one and six end points were examined in univariate analyses (median 1) and between one and seven end points (median 1) Three papers reported variations of the Cox model. Stratified Cox regression models were used in two papers and a time-dependent Cox model was compared with the standard time-fixed specification in one study. The assumptions underlying the Cox model were investigated in two papers out of 43 (5%), one by plots of the logarithm of the cumulative hazard and one by comparisons of the Cox regression estimates with those from fully parametric models (though the Cox model was presented). None of the papers assessed goodness of fit, but validation of the final model was carried out in one paper using split-sample methods.
Few papers reported examining more than ten variables (Table II) . The choice of variables to examine was related to the univariate analysis in 12 papers (being either all those used or all those found to be significant in the univariate analysis), but in 14 papers no explanation was given for the set of variables used. In a further 13 papers it was unclear which variables had been examined in the multivariate analysis. The strategy for building the multivariate model was unclear in 25 papers out of 47 (53%); over half of the remaining papers (13) used a stepwise procedure. Table V shows how the results of the multivariate analyses were presented. Half of the papers gave at least the model estimates, but six papers gave no results despite mentioning that a multivariate survival analysis had been performed. A prognostic index was computed in only two papers, and plots of survival probability based on the multivariate model were presented in six papers.
Subset analyses
Subset analyses were carried out in 52% of all papers, being the main purpose of the study in almost a fifth and with a reason given for at least some of the subset analysis in 43% of these papers. Independent analysis of complementary subsets was carried out in 39% of papers; no paper reported a test of interaction.
Abstracts
Out of 72 papers which gave a summary of length of followup in the body of the paper, 30 gave at least some of this information in the abstract and one further paper gave a different summary in the abstract and in the body of the paper. The situation was better for a summary of survival, with 42 out of the 63 who gave a summary in the body of the paper also giving at least one summary in the abstract. However, 11 papers that gave no summary of survival in the body of the paper reported a median survival or n year percentage in the abstract.
Of the 46 papers which contained both univariate and multivariate analysis, nine gave no multivariate results in the abstract and a further nine gave more emphasis to univariate than to multivariate results.
Miscellanea
Only 19% of all papers mentioned use of any statistical software, most of these using BMDP (17) and SAS (6). Software was mentioned much more often when multivariate analysis was performed, in 38% papers compared with 8% papers without multivariate analysis.
Our subjective assessment of the papers indicated poor quality of both analysis and presentation in most papers. Only in 57 papers (43%) were univariate analyses felt to be adequate and satisfactorily presented. For 22/67 papers which presented only univariate results, we judged that multivariate analyses should have been performed. For multivariate analyses we felt that 17/47 papers performed an adequate analysis and presented results satisfactorily. All plots were felt to be acceptable in 63% papers which presented survival graphs. The description of the statistical methods was judged to be adequate in 64% of all papers, but the content and presentation of the analyses were far less satisfactory. In only 21% of all papers were presentation of univariate and multivariate analyses and graphs considered adequate.
The inclusion of a member of a department of statistics or epidemiology as an author of the paper was not related to the quality of the analyses, although it did seem to have some positive effect on the description of the statistical methods and the quality of the graphs included in the papers (Table VI) . aHowever, one paper stated whether variables were 'significant' or not. (Table I) . As well as the dates of the study, it can be helpful to provide the median follow-up time. There are, however, several ways of calculating the median, not all of which are sensible (Shuster, 1991) . The median follow-up time of all patients is of questionable value because it is directly affected by the times of the observed events. Many authors provide the median follow-up time of the survivors only, but this value can be quite unstable if the number of survivors is small. Two more plausible measures are the time from the median patient entry to the cut-off date of the study and the median time to censoring derived from a 'reverse' Kaplan-Meier analysis in which the outcomes 'dead' and 'censored' are exchanged (Shuster, 1991) . Most papers in our study which reported the median follow-up time did not explain how the median was calculated.
More seriously, the majority of papers (62%) gave an unclear description of at least one of the study end points. Specific difficulties included the failure to specify whether non-cancer deaths were treated as events or censored and failure to specify how deaths without relapse were treated in analyses of disease-free survival time. This issue is discussed by Peto et al. (1977) and Gelber and Goldhirsch (1992) . The widespread absence of adequate information about end points is rather surprising. It is hard to see how readers can adequately assess a study without this information.
The large majority of papers reported the use of the logrank test for univariate analyses, with 12% not specifying the method used. The most notable weakness that we identified was the almost complete failure to use the logrank test for trend when survival was compared in three or more ordered groups. Such failure may greatly reduce the statistical power of the analysis (Peto et al., 1977) so real associations may be missed. Only one paper used this method out of 37 which analysed such data.
The logrank test does not give any information about the actual survival experience of the patients in the study. The P-value is not a measure of the difference in survival between groups. Further, P-values alone do not indicate the direction of observed differences. Thus it is desirable also to quantify the survival for each group of interest, using the median survival time or the percentage surviving a given number of years. The comparative survival experience of two groups can be usefully assessed by the hazard ratio (Peto et al., 1977; Gelber and Goldhirsch, 1992) . When estimates such as these are given it is also desirable to supply confidence intervals (Simon, 1986; Machin and Gardner, 1989 (Collett, 1994; Dawson-Saunders and Trapp, 1994 ) and a few helpful journal articles (Peto et al., 1977; Tibshirani, 1982; Elashoff, 1983; Christensen, 1987 (Pocock et al., 1987; G0tzsche, 1989) .
Continuous variables were frequently analysed by creating categories, but the basis for the choice of categories was often missing. Five papers reported using the 'optimal' cutoff point approach, which is not recommended (Altman, 1992; Altman et al., 1994 We also identified many presentational problems. In particular, there was a general tendency to present results as P-values without quantitative results, and an absence of confidence intervals. Many of the survival plots were of poor quality. Most of the problems were not too serious, but there was considerable scope for improved presentation of information in graphs (see Greenberg et al., 1983) . However, the use of sloping lines to join Kaplan-Meier survival curves gives incorrect estimates (Peto et al., 1977) . Some of the deficiencies may have been due to limitations of the software used.
We looked at the advice currently given by each of the journals in our survey in their instructions to authors regarding statistical aspects of submitted papers. The British Journal of Cancer and the European Journal of Cancer make no mention of statistics. Cancer and the Journal of Clinical Oncology recommend authors to consult the guidelines of Simon and Wittes (1985) . The latter also recommends the guidelines of Zelen (1983) . The American Journal of Clinical Oncology refers to the 'NCI Methodologic Guidelines for Reports of Clinical Trials' published in their journal. Eight of the ten points in this unattributed document (Anonymous, 1986) are in fact taken from Simon and Wittes (1985) . The original recommendation about quality control of data was omitted.
The most quoted guidelines (Simon and Wittes, 1985) are cited in some form by three of the five journals in our study (and also by the Journal of the National Cancer Institute). Their nine points cover quality control of data; accounting for patients and describing follow-up; rates of ineligibility or missing data; the need for an intention to treat analysis in randomised trials; sample size, power and confidence intervals; planned sample size and reasons for stopping patient accrual; dangers of using non-randomised controls in treatment comparisons and the unacceptability of comparing survival of responders and non-responders; description of patients, extrapolation and subset analyses; and finally a statement of the principle of adequate description already referred to above. Zelen (1983) made a similar set of recommendations, and also discussed other issues including the early reporting of clinical trials. These two sets of sensible guidelines cover many of the issues that we investigated in our review. It is clear that many authors have not taken notice of these recommendations, and that referees and editors have not insisted that authors do so.
These sets of guidelines do not, however, include much advice on the presentation of the results of studies of survival. There seems to be little published advice elsewhere on summarising the data and presenting the results of the analyses, although some authors have considered some of the relevant issues, mostly in the context of the reporting of clinical trials (Greenberg et al., 1983; Meinert, 1986; Gelber and Goldhirsch, 1993) . Our findings suggest that guidelines for presentation of survival analysis in medical journals would be useful. Some suggested guidelines are shown in the appendix. These largely follow from the most obvious reporting deficiencies described above. The methodological standard of papers published in cancer journals could be improved if authors were made to adhere to these or similar guidelines for presentation as well as the other guidelines discussed above (Zelen, 1983; Simon and Wittes, 1985) .
